Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$54.64 - $61.3 $1.23 Million - $1.38 Million
-22,490 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$59.18 - $69.99 $414,970 - $490,769
7,012 Added 45.3%
22,490 $1.37 Million
Q1 2021

May 17, 2021

SELL
$59.31 - $78.82 $12.7 Million - $16.9 Million
-214,533 Reduced 93.27%
15,478 $1.09 Million
Q4 2020

Feb 12, 2021

SELL
$50.47 - $66.26 $843,807 - $1.11 Million
-16,719 Reduced 6.78%
230,011 $13.8 Million
Q3 2020

Nov 12, 2020

SELL
$51.97 - $63.0 $1.19 Million - $1.44 Million
-22,933 Reduced 8.5%
246,730 $14.8 Million
Q2 2020

Aug 14, 2020

BUY
$30.8 - $52.47 $1.74 Million - $2.97 Million
56,650 Added 26.59%
269,663 $14.1 Million
Q1 2020

May 12, 2020

BUY
$28.4 - $50.7 $1.24 Million - $2.22 Million
43,722 Added 25.83%
213,013 $7.14 Million
Q4 2019

Feb 14, 2020

BUY
$36.31 - $46.83 $6.15 Million - $7.93 Million
169,291 New
169,291 $7.67 Million
Q1 2019

May 14, 2019

SELL
$36.47 - $42.17 $4.88 Million - $5.64 Million
-133,693 Closed
0 $0
Q4 2018

Feb 13, 2019

SELL
$41.31 - $52.16 $1.01 Million - $1.27 Million
-24,343 Reduced 15.4%
133,693 $5.75 Million
Q3 2018

Nov 13, 2018

SELL
$32.85 - $52.0 $987,142 - $1.56 Million
-30,050 Reduced 15.98%
158,036 $7.77 Million
Q2 2018

Aug 15, 2018

BUY
$27.5 - $39.8 $566,967 - $820,556
20,617 Added 12.31%
188,086 $6.03 Million
Q1 2018

May 14, 2018

SELL
$29.98 - $46.35 $140,396 - $217,057
-4,683 Reduced 2.72%
167,469 $5.22 Million
Q4 2017

Feb 12, 2018

BUY
$31.85 - $46.95 $117,462 - $173,151
3,688 Added 2.19%
172,152 $7.86 Million
Q3 2017

Nov 14, 2017

BUY
$35.7 - $39.5 $6.01 Million - $6.65 Million
168,464
168,464 $6.33 Million

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $892M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Granahan Investment Management, LLC Portfolio

Follow Granahan Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Granahan Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Granahan Investment Management, LLC with notifications on news.